KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Treasury Shares (2018 - 2024)

Historic Treasury Shares for Alnylam Pharmaceuticals (ALNY) over the last 12 years, with Q4 2024 value amounting to $1.7 million.

  • Alnylam Pharmaceuticals' Treasury Shares rose 6698.94% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 6698.94%. This contributed to the annual value of $1.7 million for FY2024, which is 6698.94% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Treasury Shares stood at $1.7 million for Q4 2024, which was up 6698.94% from $1.0 million recorded in Q4 2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Treasury Shares ranged from a high of $1.7 million in Q4 2024 and a low of $1.0 million during Q4 2023
  • Over the past 5 years, Alnylam Pharmaceuticals' median Treasury Shares value was $1.1 million (recorded in 2021), while the average stood at $1.2 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 6741.57% in 2020, then plummeted by 1355.65% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Treasury Shares (Quarter) stood at $1.0 million in 2020, then rose by 8.92% to $1.1 million in 2021, then grew by 5.19% to $1.2 million in 2022, then fell by 13.56% to $1.0 million in 2023, then surged by 66.99% to $1.7 million in 2024.
  • Its last three reported values are $1.7 million in Q4 2024, $1.0 million for Q4 2023, and $1.2 million during Q4 2022.